Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.96 USD | +0.20% | +1.64% | +14.55% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- For several months, analysts have been revising their EPS estimates roughly upwards.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The firm trades with high earnings multiples: 19.16 times its 2024 earnings per share.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+14.55% | 239M | C+ | ||
+26.28% | 42.68B | B- | ||
-3.99% | 42.4B | B | ||
+45.32% | 40.04B | A | ||
-6.20% | 28.31B | C | ||
+6.36% | 24.94B | B- | ||
-21.47% | 18.96B | B | ||
+27.58% | 12.3B | C+ | ||
-2.75% | 11.95B | C+ | ||
-2.02% | 11.55B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PBYI Stock
- Ratings Puma Biotechnology, Inc.